After Sahil Shah was diagnosed with NF1, he sought ways to connect within the NF community. As a young adolescent, he found a need for additional support for others his age. Wanting to get involved and raise funds and awareness for neurofibromatosis, the idea for SketchNF was born from a conversation with his brother and a unique fundraiser, Doodle4NF.

NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company, is currently recruiting for NFX-179 for the treatment of cutaneous neurofibromas. NFX-179 is a topical, first-in-class, “soft” MEK inhibitor that is currently being evaluated in Phase 2 clinical trials in patients with NF1.

As 2022 comes to a close and we venture into 2023, we reflect on your unwavering compassion and generosity. From the bottoms of our hearts, we thank you for your continued support of the NF Network and the thousands living with neurofibromatosis. Our work wouldn't be possible without you! See how we're making a difference together.

Medford High's varsity basketball team manager, Jonathan Malerba, is making an impact on and off the court. Despite the challenges he faces fighting neurofibromatosis, Jonathan continues to pursue his love of basketball, and his team is here to support in any way they can.